...
首页> 外文期刊>Ophthalmology >Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis.
【24h】

Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis.

机译:玻璃体内伏立康唑用于治疗内源性曲霉性眼内炎。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To describe the first use of intravitreal voriconazole in a human eye for the treatment of Aspergillus endophthalmitis. DESIGN: Interventional case report. PATIENT: A 22-year-old woman receiving immunosuppressive agents 5 weeks after lung transplantation who presented with blurred vision and redness in the right eye. INTERVENTIONS: Intravitreal injection of voriconazole (100 microg/0.1 ml) with pars plana vitrectomy, given after isolation of A. terreus in the vitreous sample. Previous treatment modalities, including vitrectomy with repeated intravitreal amphotericin B and systemic voriconazole, failed to prevent deterioration. MAIN OUTCOME MEASURES: Visual acuity (VA) and ocular inflammation. RESULTS: Significant improvement was observed in VA (to 6/15) and in ocular inflammatory reaction. The patient recovered with no evidence of systemic fungal infection. CONCLUSION: Intravitreal voriconazole may be used as an adjunct to systemic treatment in patients with Aspergillus endophthalmitis. Further clinical studies are needed to determine how often this approach can safely treat this condition.
机译:目的:描述玻璃体内伏立康唑在人眼中首次用于治疗曲霉性眼内炎的用途。设计:介入病例报告。患者:一名22岁的妇女在肺移植后5周接受了免疫抑制剂,右眼视力模糊和发红。干预:在玻璃体样品中分离出土壤曲霉后,玻璃体腔内注射伏立康唑(100微克/0.1毫升)进行了pars平板玻璃体切除术。以前的治疗方式,包括玻璃体切除术,反复玻璃体内注射两性霉素B和全身伏立康唑,均无法防止病情恶化。主要观察指标:视力(VA)和眼部炎症。结果:VA(至6/15)和眼部炎症反应显着改善。患者康复,无全身真菌感染的迹象。结论:玻璃体内伏立康唑可作为全身性治疗曲霉性眼内炎的辅助药物。需要进一步的临床研究以确定这种方法可以多久安全地治疗这种疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号